These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 12868248

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Best case series 'SWAT' teams: AHRQ/NCCAM/RAND partnership facilitates review of CAM cancer treatments.
    Muscat M.
    Altern Ther Health Med; 2001; 7(5):24-6. PubMed ID: 11565398
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Lessons learned from independent central review.
    Ford R, Schwartz L, Dancey J, Dodd LE, Eisenhauer EA, Gwyther S, Rubinstein L, Sargent D, Shankar L, Therasse P, Verweij J.
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [Abstract] [Full Text] [Related]

  • 6. Quality in healthcare: asking the right questions. The next ten years: the role of CAM in the "quality cure".
    Hyman MA.
    Altern Ther Health Med; 2005 Jan; 11(3):18-20, 79. PubMed ID: 15943129
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Memorandum of understanding between the Food and Drug Administration and the U.S. Army Medical Research and Material Command. Food and Drug Administration, HHS. Notice.
    Fed Regist; 1999 May 18; 64(95):26988-91. PubMed ID: 10558528
    [Abstract] [Full Text] [Related]

  • 10. Design and testing of the use of a complementary and alternative therapies survey in women with breast cancer.
    Lengacher CA, Bennett MP, Kipp KE, Berarducci A, Cox CE.
    Oncol Nurs Forum; 2003 May 18; 30(5):811-21. PubMed ID: 12949594
    [Abstract] [Full Text] [Related]

  • 11. Crackdown on unproven cancer treatments focuses on internet marketers.
    Ross K.
    J Natl Cancer Inst; 2008 Sep 03; 100(17):1200-2. PubMed ID: 18728276
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Research-design issues in cancer-symptom-management trials using complementary and alternative medicine: lessons from the National Cancer Institute Community Clinical Oncology Program experience.
    Buchanan DR, White JD, O'Mara AM, Kelaghan JW, Smith WB, Minasian LM.
    J Clin Oncol; 2005 Sep 20; 23(27):6682-9. PubMed ID: 16170176
    [Abstract] [Full Text] [Related]

  • 16. NCCAM-industry colloquium: exploring opportunities for collaboration.
    Engel LW, Weinberg MS, Coates PM, Colloquium Planning Group.
    J Altern Complement Med; 2001 Oct 20; 7(5):579-82. PubMed ID: 11719950
    [No Abstract] [Full Text] [Related]

  • 17. FDA shortens approval periods for new cancer treatments.
    Altern Ther Health Med; 1996 Jul 20; 2(4):28. PubMed ID: 8795916
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Surveys of complementary and alternative medicine: Part II. Use of alternative and complementary cancer therapies.
    Sparber A, Wootton JC.
    J Altern Complement Med; 2001 Jun 20; 7(3):281-7. PubMed ID: 11439851
    [Abstract] [Full Text] [Related]

  • 20. ACCF issues consensus report on CAM.
    Explore (NY); 2005 Nov 20; 1(6):427-8. PubMed ID: 16786615
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.